ClinicalTrials.gg
CompletedNCT03881059Updated Feb 15, 2022Results posted

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

A Phase 2 interventional study of BMS-986165 Placebo and BMS-986165 Dose A in Active Psoriatic Arthritis, sponsored by Bristol-Myers Squibb. Completed at 94 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-15.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 3 of them phase 3. Arthritis, Psoriatic · Bristol-Myers Squibb.

Started
2019
with 2 others
Phase 2
2 of 12
none open now
Registered
7th of 12
by date

Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, this one is one of 3 that started in 2019, is one of 2 in phase 2, and was the 7th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

1 of the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb is open now. Recruiting first, the newest first:

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily [QD]) at Week 16 in the treatment of participants with active PsA.

Read the detailed description

The study is intended to evaluate the safety and efficacy of BMS-986165 Dose A or B once daily (QD) compared with placebo in adults with active PsA. The primary endpoint is american college of rheumatology (ACR) 20 response at Week 16 (Part A).

03

Conditions studied

  • Active Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with PsA for at least 6 months before screening, and who meet the Classification Criteria for Psoriatic Arthritis (CASPAR) at screening
  • Participants either (i) cannot have prior exposure to biologics (biologic-naïve) or (ii) have failed or been intolerant to 1 tumor necrosis factor -inhibitor (TNFi) (TNFi-experienced). Failure is defined as lack of response or loss of response with at least 3 months of therapy with an approved dose of a TNFi, as judged by the investigator. Failure must have occurred at least 2 months prior to Day 1
  • Participants have at least 1 confirmed greater than or equal to (>=) 2 centimeter (cm) lesion of plaque psoriasis at screening
  • Participants have active arthritis as shown by a minimum of >= 3 swollen joints and >= 3 tender joints (66/68 joint counts) at screening and Day 1
  • High sensitivity C-reactive protein (hsCRP) >= 3milligram per liter (mg/L) at screening
  • Women of (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the start of study treatment

Exclusion criteria

Exclusion Criteria:

  • Has non-plaque psoriasis (that is (i.e.), guttate, inverse, pustular, erythrodermic or drug-induced psoriasis) at screening or Day 1
  • Has any other condition such as rheumatoid arthritis, etc. There are exceptions for inflammatory bowel disease or uveitis as follows: currently active disease is excluded but, a history of no longer active disease for at least 12 months (including not being on medication) is allowed
  • Has active (i.e. currently symptomatic) fibromyalgia
  • History or evidence of active infection and/or febrile illness within 7 days prior to Day 1 (example, bronchopulmonary, urinary, gastrointestinal, etc.)
  • History of recent serious bacterial, fungal, or viral infections requiring hospitalization and intravenous (IV) antimicrobial treatment within 90 days prior to screening, or any infection requiring antimicrobial treatment within 15 days prior to Day 1
  • History of active tuberculosis (TB) prior to screening visit, regardless of completion of adequate treatment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
203 participants (actual)

Study arms

  • Placebo comparator
    Part A: Placebo

    Other: BMS-986165 Placebo

  • Experimental
    Part A: BMS-986165 Dose A

    Drug: BMS-986165 Dose A

  • Experimental
    Part A: BMS-986165 Dose B

    Drug: BMS-986165 Dose B

  • Experimental
    Part B: Ustekinumab + BMS-986165 Placebo

    Other: BMS-986165 Placebo · Drug: Ustekinumab

  • Experimental
    Part B: BMS-986165 Dose A + Ustekinumab Placebo

    Drug: BMS-986165 Dose A · Other: Ustekinumab Placebo

  • Experimental
    Part B: BMS-986165 Dose B + Ustekinumab Placebo

    Drug: BMS-986165 Dose B · Other: Ustekinumab Placebo

Interventions

  • OtherBMS-986165 Placebo

    Participants will receive BMS-986165 matching placebo QD

  • Participants will receive BMS-986165 Dose A QD.

  • Participants will receive BMS-986165 dose B QD.

  • Participants will receive ustekinumab SQ injection QD.

  • OtherUstekinumab Placebo

    Participants will receive ustekinumab SQ matching placebo QD

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving the American College of Rheumatology (ACR) 20 Response at Week 16

    A participant is considered an ACR 20 responder if the following three conditions are met: 1) ≥ 20% improvement from baseline in the number of tender joints (68 joint count). 2) ≥ 20% improvement from baseline in the number of swollen joints (66 joint count). 3) ≥ 20% improvement from baseline in at least 3 of the following 5 domains: o Subject Global Assessment of disease activity o Physician Global Assessment of psoriatic arthritis o Subject Global Assessment of pain o Health Assessment Questionnaire-Disability Index (HAQ-DI) o High-sensitivity C-reactive protein (hsCRP)

    Time frame: 16 weeks after first dose

Secondary outcomes

  1. Adjusted Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI)

    The HAQ-DI is measured by the use of a patient-reported outcome measure questionnaire, assessing the degree of difficulty a person has experienced during the past week in 8 domains of daily living activities. Each activity category consists of 2 to 3 questions (total of 20 questions). For reach question the level of activity is scored from 0 to 3, with 0 representing "no difficulty" and 3 as "unable to do". Any activity that requires assistance from another individual or an assistive device adjusts to a minimum score of 2. For each activity category, the highest score reported in the 2 or 3 questions pertinent to that category represents the category score. Scores from the 8 categories are then summed and divided by 8 to generate the final score. The final score can range from 0 (most desirable outcome) to 3 (least desirable outcome). Adjusted change represents a change from baseline based on statistical model.

    Time frame: From baseline (day of the first dose) to 16 weeks after first dose

  2. Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 75 Response

    The PASI is a measure of the average erythema, induration thickness and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI 75 response rate represents the percentage of participants who experienced at least a 75% improvement in PASI score as compared with the baseline value. PASI assessment was performed by trained professionals.

    Time frame: 16 weeks after first dose

  3. Adjusted Change From Baseline in the Physical Component Summary (PCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire

    The SF-36 is a patient-reported outcome measure, which includes 36 items in a Likert-type format to measure the following 8 health dimensions over the past week: 1) limitations in physical activities, such as bathing or dressing 2) limitations in social activities because of physical or emotional problems 3) limitations in usual role activities because of physical health problems 4) bodily pain 5) general mental health (psychological distress and well-being) 6) limitations in usual role activities because of emotional problems 7) vitality (energy and fatigue) and 8) general health perceptions. The 8 health dimensions assessed are grouped into 2 main components, physical and mental. Each of the 8 dimensions contribute to both the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score. PCS and MCS scores range from 0 to 100, with high scores indicating a better health status. Adjusted change represents a change from baseline based on statistical model.

    Time frame: From baseline (day of the first dose) to 16 weeks after first dose

  4. Percentage of Participants Achieving the American College of Rheumatology (ACR) 50 Response at Week 16

    A participant is considered an ACR 50 responder if the following three conditions are met: 1) ≥ 50% improvement from baseline in the number of tender joints (68 joint count). 2) ≥ 50% improvement from baseline in the number of swollen joints (66 joint count). 3) ≥ 50% improvement from baseline in at least 3 of the following 5 domains: o Subject Global Assessment of disease activity o Physician Global Assessment of psoriatic arthritis o Subject Global Assessment of pain o Health Assessment Questionnaire-Disability Index (HAQ-DI) o High-sensitivity C-reactive protein (hsCRP)

    Time frame: 16 weeks after first dose

  5. Percentage of Participants Achieving the American College of Rheumatology (ACR) 70 Response at Week 16

    A participant is considered an ACR 70 responder if the following three conditions are met: 1) ≥ 70% improvement from baseline in the number of tender joints (68 joint count). 2) ≥ 70% improvement from baseline in the number of swollen joints (66 joint count). 3) ≥ 70% improvement from baseline in at least 3 of the following 5 domains: o Subject Global Assessment of disease activity o Physician Global Assessment of psoriatic arthritis o Subject Global Assessment of pain o Health Assessment Questionnaire-Disability Index (HAQ-DI) o High-sensitivity C-reactive protein (hsCRP)

    Time frame: 16 weeks after first dose

  6. Percentage of Participants Achieving Low Disease Activity According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)

    A Disease Activity Score (DAS) is a scoring system used to assess disease activity. DAS 28 CRP is a composite outcome measure that assesses: • How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28. • C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation) • Subject Global Assessment of disease activity The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows: • \< 2.6: Disease remission • 2.6 - 3.2: Low disease activity • 3.2 - 5.1: Moderate disease activity • \> 5.1: High disease activity. Only participants with a score \< 3.2 are considered to have achieved low disease activity.

    Time frame: 16 weeks after first dose

  7. Percentage of Participants Achieving Remission According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)

    A Disease Activity Score (DAS) is a scoring system used to assess disease activity. DAS 28 CRP is a composite outcome measure that assesses: • How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28. • C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation) • Subject Global Assessment of disease activity The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows: • \< 2.6: Disease remission • 2.6 - 3.2: Low disease activity • 3.2 - 5.1: Moderate disease activity • \> 5.1: High disease activity. Only participants with a score \< 2.6 are considered to have achieved remission.

    Time frame: 16 weeks after first dose

  8. Adjusted Change From Baseline in the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP) Score

    A Disease Activity Score (DAS) is a scoring system used to assess disease activity. DAS 28 CRP is a composite outcome measure that assesses: • How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28. • C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation) • Subject Global Assessment of disease activity The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows: • \< 2.6: Disease remission • 2.6 - 3.2: Low disease activity • 3.2 - 5.1: Moderate disease activity • \> 5.1: High disease activity. Adjusted change represents a change from baseline based on statistical model.

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

  9. Adjusted Change From Baseline in Dactylitis Count

    The number of digits in hands and feet with dactylitis (Tender + Non-Tender) was counted and change from baseline at week 16 was assessed. Adjusted change represents a change from baseline based on statistical model.

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

  10. Adjusted Change From Baseline in the Leeds Dactylitis Index (LDI) Basic Score

    The Leeds Dactylitis Index (LDI) Basic is a quantitative measurement of dactylitis in the 20 digits using a dactylometer. The circumference of the affected and contralateral digits, and tenderness of the affected digits are measured to generate a total score. For each dactylitic digit, the final score is defined as: \[{(A/B) - 1}\*100\]\*C, where A is circumference of involved digit, B is circumference of the opposite, unaffected, digit or reference, and C is tenderness (0 or 1). The total score is determined by summing the relative score of all digits. A higher score indicates worse dactylitis. Adjusted change represents a change from baseline based on statistical model.

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

  11. Percentage of Participants Achieving Dactylitis Resolution

    Dactylitis resolution (tender digits only) is defined as a dactylitis count of 0 in participants with dactylitis count ≥ 1 at baseline

    Time frame: 16 weeks after first dose

  12. Adjusted Change From Baseline in Enthesitis by the Leeds Enthesitis Index (LEI)

    The LEI was developed specifically for psoriatic arthritis. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden. Adjusted change represents a change from baseline based on statistical model.

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

  13. Adjusted Change From Baseline in Enthesitis by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index

    The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (R/L), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and the supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation. Adjusted change represents a change from baseline based on statistical model.

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

  14. Percentage of Participants Achieving Enthesitis Resolution by the Leeds Enthesitis Index (LEI)

    The LEI was developed specifically for psoriatic arthritis. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden. Enthesitis resolution is defined as s LEI score of 0, in subjects with LEI ≥ 1 at baseline

    Time frame: 16 weeks after first dose

  15. Percentage of Participants Achieving Enthesitis Resolution by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index

    The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (R/L), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and the supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation. Enthesitis resolution defined as a SPARCC enthesitis index score of 0, in subjects with SPARCC ≥ 1 at baseline.

    Time frame: 16 weeks after first dose

  16. Percentage of Participants Achieving a Physicians Global Assessment-Fingernails (PGA-F) Score of 0 or 1

    In participants with psoriasis fingernail involvement, the PGA-F score is used to evaluate the overall condition of the fingernails in terms of disease severity. The assessment is performed by the investigator, who rates the fingernail condition on a 5-point scale based on the higher of the nail bed/nail matrix score. Scores are 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe).

    Time frame: 16 weeks after first dose

  17. Percentage of Participants Achieving Minimal Disease Activity (MDA) Response

    A Minimal Disease Activity (MDA) responder is defined as a participant fulfilling 5 of the following 7 outcomes: • Tender joint count ≤ 1 • Swollen joint count ≤ 1 • Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3% • Subject Global Assessment of pain ≤ 15 • Subject Global Assessment of disease activity ≤ 20 • Health Assessment Questionnaire-Disability Index (HAQ-DI) ≤ 0.5 • Tender entheseal points ≤ 1

    Time frame: 16 weeks after first dose

  18. Adjusted Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS)

    PASDAS is a composite measure calculated from the Physician Global Assessment of psoriatic arthritis, the Subject Global Assessment of disease activity, the Short Form Health Survey-36 Item (SF-36) Physical Component Summary (PCS), the swollen joint count, the tender joint count, the Leeds Enthesitis Index (LEI), the Leeds Dactylitis Index (LDI) (Basic), and the the levels of high-sensitivity C-reactive Protein (hsCRP). Each item contributes differently to the final score, which ranges from 0 to 10 (higher scores represent a higher level of disease activity). Adjusted change represents a change from baseline based on statistical model.

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

  19. Adjusted Change From Baseline in the Disease Activity Index for Psoriatic Arthritis Score (DAPSA)

    DAPSA is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender/painful joint count 68, swollen joint count 66, Subject Global Assessment of disease activity, Subject Global Assessment of pain, and the levels of C-reactive Protein (CRP). Final scores are interpreted as follows: - ≤4 = Remission (REM) - \> 4 and ≤ 28 = moderate disease activity (MDA) - \>28 = high disease activity (HDA). Adjusted change represents a change from baseline based on statistical model.

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

  20. Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)

    PsARC consists of 4 measurements: tender/painful joint count, swollen joint count, Physician Global Assessment of psoriatic arthritis, and Subject Global Assessment of pain ≤ 15. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, one of which must be joint pain or swelling, without worsening in any measure.

    Time frame: 16 weeks after first dose

  21. Adjusted Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

    In participants with baseline evidence of Psoriatic Arthritis Spondylitis, symptoms are evaluated using the BASDAI, which consists of a 0 to 100 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: • Fatigue (medical) • Spinal pain • Joint pain and swelling • Areas of localized tenderness • Morning stiffness duration • Morning stiffness severity A higher count indicates worse disease. Adjusted change represents a change from baseline based on statistical model.

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

  22. Adjusted Change From Baseline in the Mental Component Summary (MCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire

    The SF-36 is a patient-reported outcome measure, which includes 36 items in a Likert-type format to measure the following 8 health dimensions over the past week: 1) limitations in physical activities, such as bathing or dressing 2) limitations in social activities because of physical or emotional problems 3) limitations in usual role activities because of physical health problems 4) bodily pain 5) general mental health (psychological distress and well-being) 6) limitations in usual role activities because of emotional problems 7) vitality (energy and fatigue) and 8) general health perceptions. The 8 health dimensions assessed are grouped into 2 main components, physical and mental. Each of the 8 dimensions contribute to both the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score. PCS and MCS scores range from 0 to 100, with high scores indicating a better health status. Adjusted change represents a change from baseline based on statistical model.

    Time frame: From baseline (day of the first dose) to 16 weeks after first dose

  23. Adjusted Change From Baseline in the Psoriatic Arthritis Impact of Disease (PsAID) 12 Score

    PsAID is a 12-item self-report that measures psoriatic arthritis symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale, and each item contributes differently to the final score. Weighted scores for each item are summed and divided by 20 to generate the final score, ranging from 0 to 10 (higher values indicate worse health). Adjusted change represents a change from baseline based on statistical model.

    Time frame: From baseline (day of the first dose) to 16 weeks after first dose

  24. Adjusted Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score

    The FACIT-Fatigue instrument is a questionnaire used to evaluate a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The questionnaire is composed of 13 questions (Short Form 13a) and each question is scored from 1 to 5. The final score results from the sum of the scores of the 13 questions, and ranges from 13 (most desirable outcome) to 65 (least desirable outcome). Adjusted change represents a change from baseline based on statistical model.

    Time frame: From baseline (day of the first dose) to 16 weeks after first dose

  25. Adjusted Change From Baseline in the Work Limitation Questionnaire (WLQ) Score

    The Work Limitation Questionnaire (WLQ) is a 25-item self-report that measures the on-the-job impact of chronic health conditions and treatment over the past 2 weeks. It focuses on assessing limitations while performing specific job demands from the following 4 domains: 1) Time management: difficulty with handling time and scheduling demands (5 items) 2) Physical demands: ability to perform job tasks that involve bodily strength, movement, endurance, coordination, and flexibility (6 items) 3) Mental-interpersonal demands: cognitively demanding tasks and on-the-job social interactions (9 items) 4) Output demands: concerns reduced work productivity (5 items). Final score ranges from 0 (limited none of the time) to 100 (limited all of the time). The score can be used to calculate a percent of lost work productivity due to a particular disease state. Adjusted change represents a change from baseline based on statistical model.

    Time frame: From baseline (day of the first dose) to 16 weeks after first dose

  26. Percentage of Participants Achieving Health Assessment Questionnaire-Disability Index (HAQ-DI) 0.35 Response

    The HAQ-DI is measured by the use of a patient-reported outcome measure questionnaire, assessing the degree of difficulty a person has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 questions (total of 20 questions). For reach question the level of activity is scored from 0 ("no difficulty") to 3 ("unable to do"). For each activity category, the highest score reported in the 2 or 3 questions pertinent to that category represents the category score. Scores from the 8 categories are then summed and divided by 8 to generate the final score. The final score can range from 0 (most desirable outcome) to 3 (least desirable outcome). A HAQ-DI 0.35 responder is defined as a participant with an improvement from baseline in HAQ-DI score of at least 0.35.

    Time frame: 16 weeks after first dose

  27. Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 90 Response

    The PASI is a measure of the average erythema, induration thickness and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI 90 response rate represents the percentage of participants who experienced at least a 90% improvement in PASI score as compared with the baseline value. PASI assessment was performed by trained professionals.

    Time frame: 16 weeks after first dose

  28. Change From Baseline in Electrocardiogram (ECG) Results

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

  29. Change From Baseline in Electrocardiogram (ECG) Heart Rate

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

  30. Change From Baseline in Vital Signs - Diastolic Blood Pressure

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

  31. Change From Baseline in Vital Signs - Heart Rate

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

  32. Change From Baseline in Vital Signs - Respiratory Rate

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

  33. Change From Baseline in Vital Signs - Systolic Blood Pressure

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

  34. Change From Baseline in Vital Signs - Temperature

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

  35. Change From Baseline in Vital Signs - Weight

    Time frame: From baseline (day of first dose) to 16 weeks after first dose

07

Results

Posted May 17, 2021

Participant flow

Treatment Period - Part A
Participant flow — Treatment Period - Part A
MilestonePlaceboBMS-986165 6 mgBMS-986165 12 mg
Started667067
Completed586359
Not completed878
Withdrew: Adverse event134
Withdrew: Randomized by mistake with study treatment011
Withdrew: Withdrawal by subject523
Withdrew: Other reasons210
Treatment Period - Part B
Participant flow — Treatment Period - Part B
MilestonePlaceboBMS-986165 6 mgBMS-986165 12 mg
Started556058
Participants maintaining same treatment as in part a01316
Participants treated with ustekinumab in part b554742
Completed475447
Not completed8611
Withdrew: Adverse event003
Withdrew: Death011
Withdrew: Lack of efficacy110
Withdrew: Lost to follow-up110
Withdrew: Site terminated by sponsor103
Withdrew: Withdrawal by subject101
Withdrew: Other reasons433

Outcome measures

PrimaryPercentage of Participants Achieving the American College of Rheumatology (ACR) 20 Response at Week 16

A participant is considered an ACR 20 responder if the following three conditions are met: 1) ≥ 20% improvement from baseline in the number of tender joints (68 joint count). 2) ≥ 20% improvement from baseline in the number of swollen joints (66 joint count). 3) ≥ 20% improvement from baseline in at least 3 of the following 5 domains: o Subject Global Assessment of disease activity o Physician Global Assessment of psoriatic arthritis o Subject Global Assessment of pain o Health Assessment Questionnaire-Disability Index (HAQ-DI) o High-sensitivity C-reactive protein (hsCRP)

Time frame:
16 weeks after first dose
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving the American College of Rheumatology (ACR) 20 Response at Week 16
Percent of ParticipantsPlaceboBMS-986165 6 mgBMS-986165 12 mg
Percentage of Participants Achieving the American College of Rheumatology (ACR) 20 Response at Week 1631.8 (20.6 to 43.1)52.9 (41.2 to 64.6)62.7 (51.1 to 74.3)
Statistical analysis
  • Placebo vs BMS-986165 6 mg vs BMS-986165 12 mg · Regression, Logistic · p = <0.001 · Slope coefficient of dose: 0.11 · 95% CI 0.05 to 0.17
SecondaryAdjusted Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI)

The HAQ-DI is measured by the use of a patient-reported outcome measure questionnaire, assessing the degree of difficulty a person has experienced during the past week in 8 domains of daily living activities. Each activity category consists of 2 to 3 questions (total of 20 questions). For reach question the level of activity is scored from 0 to 3, with 0 representing "no difficulty" and 3 as "unable to do". Any activity that requires assistance from another individual or an assistive device adjusts to a minimum score of 2. For each activity category, the highest score reported in the 2 or 3 questions pertinent to that category represents the category score. Scores from the 8 categories are then summed and divided by 8 to generate the final score. The final score can range from 0 (most desirable outcome) to 3 (least desirable outcome). Adjusted change represents a change from baseline based on statistical model.

Time frame:
From baseline (day of the first dose) to 16 weeks after first dose
Reported as:
Mean · Score on a scale
Adjusted Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI)
Score on a scalePlaceboBMS-986165 6 mgBMS-986165 12 mg
Adjusted Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI)-0.11 ± 0.066-0.37 ± 0.065-0.39 ± 0.067
SecondaryPercentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 75 Response

The PASI is a measure of the average erythema, induration thickness and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI 75 response rate represents the percentage of participants who experienced at least a 75% improvement in PASI score as compared with the baseline value. PASI assessment was performed by trained professionals.

Time frame:
16 weeks after first dose
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 75 Response
Percent of ParticipantsPlaceboBMS-986165 6 mgBMS-986165 12 mg
Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 75 Response20.4 (9.6 to 31.1)42.4 (29.8 to 55.0)59.6 (46.3 to 73.0)
SecondaryAdjusted Change From Baseline in the Physical Component Summary (PCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire

The SF-36 is a patient-reported outcome measure, which includes 36 items in a Likert-type format to measure the following 8 health dimensions over the past week: 1) limitations in physical activities, such as bathing or dressing 2) limitations in social activities because of physical or emotional problems 3) limitations in usual role activities because of physical health problems 4) bodily pain 5) general mental health (psychological distress and well-being) 6) limitations in usual role activities because of emotional problems 7) vitality (energy and fatigue) and 8) general health perceptions. The 8 health dimensions assessed are grouped into 2 main components, physical and mental. Each of the 8 dimensions contribute to both the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score. PCS and MCS scores range from 0 to 100, with high scores indicating a better health status. Adjusted change represents a change from baseline based on statistical model.

Time frame:
From baseline (day of the first dose) to 16 weeks after first dose
Reported as:
Mean · Score on a scale
Adjusted Change From Baseline in the Physical Component Summary (PCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire
Score on a scalePlaceboBMS-986165 6 mgBMS-986165 12 mg
Adjusted Change From Baseline in the Physical Component Summary (PCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire2.3 ± 0.975.6 ± 0.945.8 ± 0.97
SecondaryPercentage of Participants Achieving the American College of Rheumatology (ACR) 50 Response at Week 16

A participant is considered an ACR 50 responder if the following three conditions are met: 1) ≥ 50% improvement from baseline in the number of tender joints (68 joint count). 2) ≥ 50% improvement from baseline in the number of swollen joints (66 joint count). 3) ≥ 50% improvement from baseline in at least 3 of the following 5 domains: o Subject Global Assessment of disease activity o Physician Global Assessment of psoriatic arthritis o Subject Global Assessment of pain o Health Assessment Questionnaire-Disability Index (HAQ-DI) o High-sensitivity C-reactive protein (hsCRP)

Time frame:
16 weeks after first dose
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving the American College of Rheumatology (ACR) 50 Response at Week 16
Percent of ParticipantsPlaceboBMS-986165 6 mgBMS-986165 12 mg
Percentage of Participants Achieving the American College of Rheumatology (ACR) 50 Response at Week 1610.6 (3.2 to 18.0)24.3 (14.2 to 34.3)32.8 (21.6 to 44.1)
SecondaryPercentage of Participants Achieving the American College of Rheumatology (ACR) 70 Response at Week 16

A participant is considered an ACR 70 responder if the following three conditions are met: 1) ≥ 70% improvement from baseline in the number of tender joints (68 joint count). 2) ≥ 70% improvement from baseline in the number of swollen joints (66 joint count). 3) ≥ 70% improvement from baseline in at least 3 of the following 5 domains: o Subject Global Assessment of disease activity o Physician Global Assessment of psoriatic arthritis o Subject Global Assessment of pain o Health Assessment Questionnaire-Disability Index (HAQ-DI) o High-sensitivity C-reactive protein (hsCRP)

Time frame:
16 weeks after first dose
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving the American College of Rheumatology (ACR) 70 Response at Week 16
Percent of ParticipantsPlaceboBMS-986165 6 mgBMS-986165 12 mg
Percentage of Participants Achieving the American College of Rheumatology (ACR) 70 Response at Week 161.5 (0.0 to 4.5)14.3 (6.1 to 22.5)19.4 (9.9 to 28.9)
SecondaryPercentage of Participants Achieving Low Disease Activity According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)

A Disease Activity Score (DAS) is a scoring system used to assess disease activity. DAS 28 CRP is a composite outcome measure that assesses: • How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28. • C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation) • Subject Global Assessment of disease activity The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows: • \< 2.6: Disease remission • 2.6 - 3.2: Low disease activity • 3.2 - 5.1: Moderate disease activity • \> 5.1: High disease activity. Only participants with a score \< 3.2 are considered to have achieved low disease activity.

Time frame:
16 weeks after first dose
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving Low Disease Activity According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)
Percent of ParticipantsPlaceboBMS-986165 6 mgBMS-986165 12 mg
Percentage of Participants Achieving Low Disease Activity According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)22.7 (12.6 to 32.8)37.1 (25.8 to 48.5)43.3 (31.4 to 55.1)
SecondaryPercentage of Participants Achieving Remission According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)

A Disease Activity Score (DAS) is a scoring system used to assess disease activity. DAS 28 CRP is a composite outcome measure that assesses: • How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28. • C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation) • Subject Global Assessment of disease activity The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows: • \< 2.6: Disease remission • 2.6 - 3.2: Low disease activity • 3.2 - 5.1: Moderate disease activity • \> 5.1: High disease activity. Only participants with a score \< 2.6 are considered to have achieved remission.

Time frame:
16 weeks after first dose
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving Remission According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)
Percent of ParticipantsPlaceboBMS-986165 6 mgBMS-986165 12 mg
Percentage of Participants Achieving Remission According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)6.1 (0.3 to 11.8)24.3 (14.2 to 34.3)25.4 (15.0 to 35.8)
SecondaryAdjusted Change From Baseline in the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP) Score

A Disease Activity Score (DAS) is a scoring system used to assess disease activity. DAS 28 CRP is a composite outcome measure that assesses: • How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28. • C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation) • Subject Global Assessment of disease activity The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows: • \< 2.6: Disease remission • 2.6 - 3.2: Low disease activity • 3.2 - 5.1: Moderate disease activity • \> 5.1: High disease activity. Adjusted change represents a change from baseline based on statistical model.

Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · Score on a scale
Adjusted Change From Baseline in the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP) Score
Score on a scalePlaceboBMS-986165 6 mgBMS-986165 12 mg
Adjusted Change From Baseline in the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP) Score-0.9 ± 0.15-1.7 ± 0.15-1.7 ± 0.15
SecondaryAdjusted Change From Baseline in Dactylitis Count

The number of digits in hands and feet with dactylitis (Tender + Non-Tender) was counted and change from baseline at week 16 was assessed. Adjusted change represents a change from baseline based on statistical model.

Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · Digits with dactylitis
Adjusted Change From Baseline in Dactylitis Count
Digits with dactylitisPlaceboBMS-986165 6 mgBMS-986165 12 mg
Adjusted Change From Baseline in Dactylitis Count-1.8 ± 0.40-2.0 ± 0.38-2.5 ± 0.38
SecondaryAdjusted Change From Baseline in the Leeds Dactylitis Index (LDI) Basic Score

The Leeds Dactylitis Index (LDI) Basic is a quantitative measurement of dactylitis in the 20 digits using a dactylometer. The circumference of the affected and contralateral digits, and tenderness of the affected digits are measured to generate a total score. For each dactylitic digit, the final score is defined as: \[{(A/B) - 1}\*100\]\*C, where A is circumference of involved digit, B is circumference of the opposite, unaffected, digit or reference, and C is tenderness (0 or 1). The total score is determined by summing the relative score of all digits. A higher score indicates worse dactylitis. Adjusted change represents a change from baseline based on statistical model.

Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · Score on a scale
Adjusted Change From Baseline in the Leeds Dactylitis Index (LDI) Basic Score
Score on a scalePlaceboBMS-986165 6 mgBMS-986165 12 mg
Adjusted Change From Baseline in the Leeds Dactylitis Index (LDI) Basic Score-28.3 ± 8.87-41.8 ± 8.35-44.5 ± 8.90
SecondaryPercentage of Participants Achieving Dactylitis Resolution

Dactylitis resolution (tender digits only) is defined as a dactylitis count of 0 in participants with dactylitis count ≥ 1 at baseline

Time frame:
16 weeks after first dose
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving Dactylitis Resolution
Percent of ParticipantsPlaceboBMS-986165 6 mgBMS-986165 12 mg
Percentage of Participants Achieving Dactylitis Resolution60.0 (40.8 to 79.2)76.7 (61.5 to 91.8)79.2 (62.9 to 95.4)
SecondaryAdjusted Change From Baseline in Enthesitis by the Leeds Enthesitis Index (LEI)

The LEI was developed specifically for psoriatic arthritis. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden. Adjusted change represents a change from baseline based on statistical model.

Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · Score on a scale
Adjusted Change From Baseline in Enthesitis by the Leeds Enthesitis Index (LEI)
Score on a scalePlaceboBMS-986165 6 mgBMS-986165 12 mg
Adjusted Change From Baseline in Enthesitis by the Leeds Enthesitis Index (LEI)-1.2 ± 0.27-1.5 ± 0.25-1.7 ± 0.28
SecondaryAdjusted Change From Baseline in Enthesitis by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index

The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (R/L), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and the supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation. Adjusted change represents a change from baseline based on statistical model.

Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · Score on a scale
Adjusted Change From Baseline in Enthesitis by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index
Score on a scalePlaceboBMS-986165 6 mgBMS-986165 12 mg
Adjusted Change From Baseline in Enthesitis by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index-1.2 ± 0.54-2.9 ± 0.48-3.1 ± 0.51
SecondaryPercentage of Participants Achieving Enthesitis Resolution by the Leeds Enthesitis Index (LEI)

The LEI was developed specifically for psoriatic arthritis. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden. Enthesitis resolution is defined as s LEI score of 0, in subjects with LEI ≥ 1 at baseline

Time frame:
16 weeks after first dose
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving Enthesitis Resolution by the Leeds Enthesitis Index (LEI)
Percent of ParticipantsPlaceboBMS-986165 6 mgBMS-986165 12 mg
Percentage of Participants Achieving Enthesitis Resolution by the Leeds Enthesitis Index (LEI)22.6 (7.9 to 37.3)51.3 (35.6 to 67.0)50.0 (30.8 to 69.2)
SecondaryPercentage of Participants Achieving Enthesitis Resolution by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index

The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (R/L), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and the supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation. Enthesitis resolution defined as a SPARCC enthesitis index score of 0, in subjects with SPARCC ≥ 1 at baseline.

Time frame:
16 weeks after first dose
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving Enthesitis Resolution by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index
Percent of ParticipantsPlaceboBMS-986165 6 mgBMS-986165 12 mg
Percentage of Participants Achieving Enthesitis Resolution by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index17.6 (4.8 to 30.5)51.2 (36.2 to 66.1)41.2 (24.6 to 57.7)
SecondaryPercentage of Participants Achieving a Physicians Global Assessment-Fingernails (PGA-F) Score of 0 or 1

In participants with psoriasis fingernail involvement, the PGA-F score is used to evaluate the overall condition of the fingernails in terms of disease severity. The assessment is performed by the investigator, who rates the fingernail condition on a 5-point scale based on the higher of the nail bed/nail matrix score. Scores are 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe).

Time frame:
16 weeks after first dose
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving a Physicians Global Assessment-Fingernails (PGA-F) Score of 0 or 1
Percent of ParticipantsPlaceboBMS-986165 6 mgBMS-986165 12 mg
Percentage of Participants Achieving a Physicians Global Assessment-Fingernails (PGA-F) Score of 0 or 10 (0.0 to 0.0)21.4 (0.0 to 42.9)50.0 (28.1 to 71.9)
SecondaryPercentage of Participants Achieving Minimal Disease Activity (MDA) Response

A Minimal Disease Activity (MDA) responder is defined as a participant fulfilling 5 of the following 7 outcomes: • Tender joint count ≤ 1 • Swollen joint count ≤ 1 • Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3% • Subject Global Assessment of pain ≤ 15 • Subject Global Assessment of disease activity ≤ 20 • Health Assessment Questionnaire-Disability Index (HAQ-DI) ≤ 0.5 • Tender entheseal points ≤ 1

Time frame:
16 weeks after first dose
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving Minimal Disease Activity (MDA) Response
Percent of ParticipantsPlaceboBMS-986165 6 mgBMS-986165 12 mg
Percentage of Participants Achieving Minimal Disease Activity (MDA) Response7.6 (1.2 to 14.0)22.9 (13.0 to 32.7)23.9 (13.7 to 34.1)
SecondaryAdjusted Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS)

PASDAS is a composite measure calculated from the Physician Global Assessment of psoriatic arthritis, the Subject Global Assessment of disease activity, the Short Form Health Survey-36 Item (SF-36) Physical Component Summary (PCS), the swollen joint count, the tender joint count, the Leeds Enthesitis Index (LEI), the Leeds Dactylitis Index (LDI) (Basic), and the the levels of high-sensitivity C-reactive Protein (hsCRP). Each item contributes differently to the final score, which ranges from 0 to 10 (higher scores represent a higher level of disease activity). Adjusted change represents a change from baseline based on statistical model.

Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · Score on a scale
Adjusted Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS)
Score on a scalePlaceboBMS-986165 6 mgBMS-986165 12 mg
Adjusted Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS)-1.1 ± 0.21-2.0 ± 0.20-2.1 ± 0.20
SecondaryAdjusted Change From Baseline in the Disease Activity Index for Psoriatic Arthritis Score (DAPSA)

DAPSA is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender/painful joint count 68, swollen joint count 66, Subject Global Assessment of disease activity, Subject Global Assessment of pain, and the levels of C-reactive Protein (CRP). Final scores are interpreted as follows: - ≤4 = Remission (REM) - \> 4 and ≤ 28 = moderate disease activity (MDA) - \>28 = high disease activity (HDA). Adjusted change represents a change from baseline based on statistical model.

Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · Score on a scale
Adjusted Change From Baseline in the Disease Activity Index for Psoriatic Arthritis Score (DAPSA)
Score on a scalePlaceboBMS-986165 6 mgBMS-986165 12 mg
Adjusted Change From Baseline in the Disease Activity Index for Psoriatic Arthritis Score (DAPSA)-13.3 ± 2.20-23.2 ± 2.16-25.6 ± 2.23
SecondaryPercentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)

PsARC consists of 4 measurements: tender/painful joint count, swollen joint count, Physician Global Assessment of psoriatic arthritis, and Subject Global Assessment of pain ≤ 15. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, one of which must be joint pain or swelling, without worsening in any measure.

Time frame:
16 weeks after first dose
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)
Percent of ParticipantsPlaceboBMS-986165 6 mgBMS-986165 12 mg
Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)54.5 (42.5 to 66.6)75.7 (65.7 to 85.8)74.6 (64.2 to 85.0)
SecondaryAdjusted Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

In participants with baseline evidence of Psoriatic Arthritis Spondylitis, symptoms are evaluated using the BASDAI, which consists of a 0 to 100 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: • Fatigue (medical) • Spinal pain • Joint pain and swelling • Areas of localized tenderness • Morning stiffness duration • Morning stiffness severity A higher count indicates worse disease. Adjusted change represents a change from baseline based on statistical model.

Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · Score on a scale
Adjusted Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Score on a scalePlaceboBMS-986165 6 mgBMS-986165 12 mg
Adjusted Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)-1.7 ± 0.55-2.0 ± 0.48-2.2 ± 0.57
SecondaryAdjusted Change From Baseline in the Mental Component Summary (MCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire

The SF-36 is a patient-reported outcome measure, which includes 36 items in a Likert-type format to measure the following 8 health dimensions over the past week: 1) limitations in physical activities, such as bathing or dressing 2) limitations in social activities because of physical or emotional problems 3) limitations in usual role activities because of physical health problems 4) bodily pain 5) general mental health (psychological distress and well-being) 6) limitations in usual role activities because of emotional problems 7) vitality (energy and fatigue) and 8) general health perceptions. The 8 health dimensions assessed are grouped into 2 main components, physical and mental. Each of the 8 dimensions contribute to both the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score. PCS and MCS scores range from 0 to 100, with high scores indicating a better health status. Adjusted change represents a change from baseline based on statistical model.

Time frame:
From baseline (day of the first dose) to 16 weeks after first dose
Reported as:
Mean · Score on a scale
Adjusted Change From Baseline in the Mental Component Summary (MCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire
Score on a scalePlaceboBMS-986165 6 mgBMS-986165 12 mg
Adjusted Change From Baseline in the Mental Component Summary (MCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire0.7 ± 1.003.6 ± 0.973.5 ± 1.01
SecondaryAdjusted Change From Baseline in the Psoriatic Arthritis Impact of Disease (PsAID) 12 Score

PsAID is a 12-item self-report that measures psoriatic arthritis symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale, and each item contributes differently to the final score. Weighted scores for each item are summed and divided by 20 to generate the final score, ranging from 0 to 10 (higher values indicate worse health). Adjusted change represents a change from baseline based on statistical model.

Time frame:
From baseline (day of the first dose) to 16 weeks after first dose
Reported as:
Mean · Score on a scale
Adjusted Change From Baseline in the Psoriatic Arthritis Impact of Disease (PsAID) 12 Score
Score on a scalePlaceboBMS-986165 6 mgBMS-986165 12 mg
Adjusted Change From Baseline in the Psoriatic Arthritis Impact of Disease (PsAID) 12 Score-1.0 ± 0.26-2.1 ± 0.26-2.3 ± 0.26
SecondaryAdjusted Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score

The FACIT-Fatigue instrument is a questionnaire used to evaluate a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The questionnaire is composed of 13 questions (Short Form 13a) and each question is scored from 1 to 5. The final score results from the sum of the scores of the 13 questions, and ranges from 13 (most desirable outcome) to 65 (least desirable outcome). Adjusted change represents a change from baseline based on statistical model.

Time frame:
From baseline (day of the first dose) to 16 weeks after first dose
Reported as:
Mean · Score on a scale
Adjusted Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score
Score on a scalePlaceboBMS-986165 6 mgBMS-986165 12 mg
Adjusted Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score2.8 ± 1.175.6 ± 1.167.2 ± 1.18
SecondaryAdjusted Change From Baseline in the Work Limitation Questionnaire (WLQ) Score

The Work Limitation Questionnaire (WLQ) is a 25-item self-report that measures the on-the-job impact of chronic health conditions and treatment over the past 2 weeks. It focuses on assessing limitations while performing specific job demands from the following 4 domains: 1) Time management: difficulty with handling time and scheduling demands (5 items) 2) Physical demands: ability to perform job tasks that involve bodily strength, movement, endurance, coordination, and flexibility (6 items) 3) Mental-interpersonal demands: cognitively demanding tasks and on-the-job social interactions (9 items) 4) Output demands: concerns reduced work productivity (5 items). Final score ranges from 0 (limited none of the time) to 100 (limited all of the time). The score can be used to calculate a percent of lost work productivity due to a particular disease state. Adjusted change represents a change from baseline based on statistical model.

Time frame:
From baseline (day of the first dose) to 16 weeks after first dose
Reported as:
Mean · Score on a scale
Adjusted Change From Baseline in the Work Limitation Questionnaire (WLQ) Score
Score on a scalePlaceboBMS-986165 6 mgBMS-986165 12 mg
Adjusted Change From Baseline in the Work Limitation Questionnaire (WLQ) Score-1.2 ± 0.69-1.9 ± 0.67-2.7 ± 0.70
SecondaryPercentage of Participants Achieving Health Assessment Questionnaire-Disability Index (HAQ-DI) 0.35 Response

The HAQ-DI is measured by the use of a patient-reported outcome measure questionnaire, assessing the degree of difficulty a person has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 questions (total of 20 questions). For reach question the level of activity is scored from 0 ("no difficulty") to 3 ("unable to do"). For each activity category, the highest score reported in the 2 or 3 questions pertinent to that category represents the category score. Scores from the 8 categories are then summed and divided by 8 to generate the final score. The final score can range from 0 (most desirable outcome) to 3 (least desirable outcome). A HAQ-DI 0.35 responder is defined as a participant with an improvement from baseline in HAQ-DI score of at least 0.35.

Time frame:
16 weeks after first dose
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving Health Assessment Questionnaire-Disability Index (HAQ-DI) 0.35 Response
Percent of ParticipantsPlaceboBMS-986165 6 mgBMS-986165 12 mg
Percentage of Participants Achieving Health Assessment Questionnaire-Disability Index (HAQ-DI) 0.35 Response15.2 (6.5 to 23.8)38.6 (27.2 to 50.0)40.3 (28.6 to 52.0)
SecondaryPercentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 90 Response

The PASI is a measure of the average erythema, induration thickness and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI 90 response rate represents the percentage of participants who experienced at least a 90% improvement in PASI score as compared with the baseline value. PASI assessment was performed by trained professionals.

Time frame:
16 weeks after first dose
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 90 Response
Percent of ParticipantsPlaceboBMS-986165 6 mgBMS-986165 12 mg
Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 90 Response9.3 (1.5 to 17.0)20.3 (10.1 to 30.6)34.6 (21.7 to 47.5)
SecondaryChange From Baseline in Electrocardiogram (ECG) Results
Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · msec
Change From Baseline in Electrocardiogram (ECG) Results
msecPlaceboBMS-986165 6 mgBMS-986165 12 mg
PR Interval, Aggregate3.9 ± 16.403.2 ± 17.83-2.9 ± 37.09
QRS Duration, Aggregate-0.5 ± 9.073.9 ± 11.58-1.1 ± 13.55
QT Interval, Aggregate1.4 ± 27.472.7 ± 28.561.5 ± 26.81
QTcB Interval, Aggregate2.8 ± 41.79-6.7 ± 24.460.4 ± 20.34
QTcF Interval, Aggregate-0.6 ± 29.832.4 ± 29.624.4 ± 22.96
SecondaryChange From Baseline in Electrocardiogram (ECG) Heart Rate
Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · beats/min
Change From Baseline in Electrocardiogram (ECG) Heart Rate
beats/minPlaceboBMS-986165 6 mgBMS-986165 12 mg
Change From Baseline in Electrocardiogram (ECG) Heart Rate-0.7 ± 8.28-1.0 ± 9.840.0 ± 8.82
SecondaryChange From Baseline in Vital Signs - Diastolic Blood Pressure
Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · mmHg
Change From Baseline in Vital Signs - Diastolic Blood Pressure
mmHgPlaceboBMS-986165 6 mgBMS-986165 12 mg
Change From Baseline in Vital Signs - Diastolic Blood Pressure1.1 ± 8.67-0.9 ± 6.10-1.7 ± 7.06
SecondaryChange From Baseline in Vital Signs - Heart Rate
Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · beats/min
Change From Baseline in Vital Signs - Heart Rate
beats/minPlaceboBMS-986165 6 mgBMS-986165 12 mg
Change From Baseline in Vital Signs - Heart Rate0.7 ± 9.40-2.5 ± 9.020.8 ± 8.56
SecondaryChange From Baseline in Vital Signs - Respiratory Rate
Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · breaths/min
Change From Baseline in Vital Signs - Respiratory Rate
breaths/minPlaceboBMS-986165 6 mgBMS-986165 12 mg
Change From Baseline in Vital Signs - Respiratory Rate0.0 ± 1.88-0.2 ± 1.460.2 ± 1.16
SecondaryChange From Baseline in Vital Signs - Systolic Blood Pressure
Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · mmHg
Change From Baseline in Vital Signs - Systolic Blood Pressure
mmHgPlaceboBMS-986165 6 mgBMS-986165 12 mg
Change From Baseline in Vital Signs - Systolic Blood Pressure1.6 ± 11.05-0.6 ± 10.95-1.5 ± 11.44
SecondaryChange From Baseline in Vital Signs - Temperature
Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · Celsius degree (C)
Change From Baseline in Vital Signs - Temperature
Celsius degree (C)PlaceboBMS-986165 6 mgBMS-986165 12 mg
Change From Baseline in Vital Signs - Temperature-0.05 ± 0.307-0.07 ± 0.364-0.06 ± 0.323
SecondaryChange From Baseline in Vital Signs - Weight
Time frame:
From baseline (day of first dose) to 16 weeks after first dose
Reported as:
Mean · Kg
Change From Baseline in Vital Signs - Weight
KgPlaceboBMS-986165 6 mgBMS-986165 12 mg
Change From Baseline in Vital Signs - Weight-0.24 ± 3.6900.18 ± 2.6460.43 ± 2.823

Adverse events

Collected over All-cause mortality was assessed from date of first dose to study completion (up to approximately 21 months). Serious Adverse events and other adverse events were assessed from date of first dose to 30 days following date of last dose (up to approximately 13 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Only Part A:Placebo0/11 (0%)2/11 (18.2%)6/11 (54.5%)
Only Part A:BMS-986165 6 mg QD0/10 (0%)0/10 (0%)7/10 (70%)
Only Part A:BMS-986165 12 mg QD0/9 (0%)0/9 (0%)7/9 (77.8%)
Part A: Placebo + Part B: Ustekinumab SQ0/55 (0%)0/55 (0%)34/55 (61.8%)
BMS-986165 6 mg in Part A and Part B0/13 (0%)1/13 (7.7%)13/13 (100%)
Part A: BMS-986165 6 mg QD - Part B: Ustekinumab SQ1/47 (2.1%)3/47 (6.4%)30/47 (63.8%)
BMS-986165 12 mg in Part A and Part B0/16 (0%)0/16 (0%)11/16 (68.8%)
Part A: BMS-986165 12 mg QD - Part B: Ustekinumab SQ1/42 (2.4%)4/42 (9.5%)31/42 (73.8%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventOnly Part A:PlaceboOnly Part A:BMS-986165 6 mg QDOnly Part A:BMS-986165 12 mg QDPart A: Placebo + Part B: Ustekinumab SQBMS-986165 6 mg in Part A and Part BPart A: BMS-986165 6 mg QD - Part B: Ustekinumab SQBMS-986165 12 mg in Part A and Part BPart A: BMS-986165 12 mg QD - Part B: Ustekinumab SQ
Metastatic carcinoid tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/110/100/90/550/130/470/160/42
Deep vein thrombosisVascular disorders1/110/100/90/550/130/470/160/42
Psoriatic arthropathyMusculoskeletal and connective tissue disorders0/110/100/90/551/130/470/160/42
Neuropathy peripheralNervous system disorders0/110/100/90/551/130/470/160/42
Atrial fibrillationCardiac disorders0/110/100/90/550/130/470/161/42
PneumoniaInfections and infestations0/110/100/90/550/130/470/161/42
Chest injuryInjury, poisoning and procedural complications0/110/100/90/550/130/470/161/42
Road traffic accidentInjury, poisoning and procedural complications0/110/100/90/550/130/470/161/42
NauseaGastrointestinal disorders0/110/100/90/550/131/470/160/42
DeathGeneral disorders0/110/100/90/550/131/470/160/42
Most frequent other events
Showing 10 of 104
Most frequent other events
EventOnly Part A:PlaceboOnly Part A:BMS-986165 6 mg QDOnly Part A:BMS-986165 12 mg QDPart A: Placebo + Part B: Ustekinumab SQBMS-986165 6 mg in Part A and Part BPart A: BMS-986165 6 mg QD - Part B: Ustekinumab SQBMS-986165 12 mg in Part A and Part BPart A: BMS-986165 12 mg QD - Part B: Ustekinumab SQ
NasopharyngitisInfections and infestations0/110/101/97/551/136/472/1611/42
PyrexiaGeneral disorders0/111/100/90/551/130/473/161/42
PsoriasisSkin and subcutaneous tissue disorders2/111/100/92/551/131/470/160/42
Upper respiratory tract infectionInfections and infestations0/110/100/94/552/133/471/160/42
Aspartate aminotransferase increasedInvestigations0/110/100/91/552/130/471/162/42
HeadacheNervous system disorders1/111/101/96/552/136/470/161/42
HypertensionVascular disorders0/110/100/91/552/133/470/160/42
PharyngitisInfections and infestations0/110/100/91/552/131/470/162/42
Aphthous ulcerGastrointestinal disorders0/110/100/90/550/131/472/161/42
Alanine aminotransferase increasedInvestigations0/110/100/92/551/130/472/162/42

Baseline characteristics

All treated participants

Age, Continuous
Age, Continuous(Years)PlaceboBMS-986165 6 mgBMS-986165 12 mgTotal
Mean48.5 ± 13.1750.5 ± 13.6950.5 ± 13.7549.8 ± 13.51
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBMS-986165 6 mgBMS-986165 12 mgTotal
Female403034104
Male26403399
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboBMS-986165 6 mgBMS-986165 12 mgTotal
Hispanic or Latino74516
Not Hispanic or Latino596562186
Unknown or Not Reported0101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBMS-986165 6 mgBMS-986165 12 mgTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1304
White656767199
More than one race0000
Unknown or Not Reported0000
08

Study locations

94 sites
  • Rheumatology Associates of North Alabama
    Huntsville, Alabama 35801, United States
  • Medvin Clinical Research - Covina Office
    Covina, California 91722, United States
  • University of California at San Diego Medical Center
    La Jolla, California 92039, United States
  • Arthritis & Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • San Marcus Research Clinic
    Miami Lakes, Florida 33014, United States
  • Omega Research Consultants - Metrowest
    Orlando, Florida 32835, United States
  • Integral Rheumatology & Immunology Specialists
    Plantation, Florida 33324, United States
  • BayCare Medical Group
    Saint Petersburg, Florida 33705, United States
  • University of South Florida - Morsani College of Medicine
    Tampa, Florida 33612, United States
  • Heartland Research Associates - East Wichita
    Wichita, Kansas 67207, United States
  • Arthritis Center of Lexington
    Lexington, Kentucky 40504, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • Arthritis Associates
    Hattiesburg, Mississippi 39402, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Atlantic Coast Rheumatology
    Toms River, New Jersey 08755, United States
  • Albuquerque Center for Rheumatology
    Albuquerque, New Mexico 87102, United States
  • The Center for Rheumatology-Albany
    Albany, New York 12203, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Joint Muscle Medical Care and Research Institute - Lilington Office
    Charlotte, North Carolina 28204, United States
  • DJL Clinical Research
    Charlotte, North Carolina 28210, United States
  • PMG Research of Salisbury
    Salisbury, North Carolina 28144, United States
  • Paramount Medical Research and Consulting
    Middleburg Heights, Ohio 44130, United States
  • East Penn Rheumatology Associates
    Bethlehem, Pennsylvania 18015, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Low Country Rheumatology
    Summerville, South Carolina 29486, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Office of Ramesh C. Gupta, MD
    Memphis, Tennessee 38119, United States
  • Pioneer Research Solutions
    Cypress, Texas 77429-5890, United States
  • Southwest Rheumatology Research
    Mesquite, Texas 75150, United States
  • Seattle Rheumatology Associates
    Seattle, Washington 98122, United States
  • Arthritis Northwest Rheumatology
    Spokane, Washington 99204, United States
  • L.K.N. Arthrocentrum, s.r.o
    Hlu?, 748 01, Czechia
  • CCR Ostrava
    Ostrava, 702 00, Czechia
  • Revmatologie MUDr. Klara Sirova s.r.o.
    Ostrava, 702 00, Czechia
  • Arthrocentrum
    Praha 10, 101 00, Czechia
  • Affidea Praha
    Praha 11 Chodov, 148 00, Czechia
  • CCR Prague
    Praha 3, 130 00, Czechia
  • Nuselska Poliklinika
    Praha 4, 140 00, Czechia
  • Revmatologicky Ustav
    Praha, 128 00, Czechia
  • PV-Medical Services, s.r.o.
    Zlin, 760 01, Czechia
  • Charite Universitatsmedizin Berlin
    Berlin, 10117, Germany
  • Rheumatologische Schwerpunktpraxis PD Dr. med. Brandt Jurgens
    Berlin, 12161, Germany
  • Universitatsklinikum Erlangen
    Erlangen, 91054, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt am Main, 60590, Germany
  • HRF II - Hamburger Rheuma Forschungszentrum II - MVZ fur Rheumatologie und Autoimmunmedizin Hamburg
    Hamburg, 20095, Germany
  • SMO.MD GmbH
    Magdeburg, 39120, Germany
  • Universitatsmedizin Mannheim
    Mannheim, 68167, Germany
  • Klinikum der Universitat Munchen
    Munchen, 80336, Germany
  • Clinexpert Gyogycentrum
    Budapest, 1033, Hungary
  • Magyar Honvedseg Egeszsegugyi Kozpont
    Budapest, 1062, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • CRU Hungary Egeszsegugyi es Szolgaltato Korlatolt Felelossegu Tarsasag
    Miskolc, 3529, Hungary
  • Aranyklinika
    Szeged, 6720, Hungary
  • CMed Rehabilitacios es Diagnosztikai Kozpont
    Szekesfehervar, 8000, Hungary
  • Csongrad Megyei Dr. Bugyi Istvan Korhaz
    Szentes, 6600, Hungary
  • Azienda Ospedaliera Universitaria Integrata di Verona
    Verona, 37134, Italy
  • Osteo-Medic
    Bia?ystok, 15-351, Poland
  • Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk
    Bialystok, 15-077, Poland
  • ClinicMed Daniluk Nowak Spolka Jawna
    Bialystok, 15-879, Poland
  • Nasz Lekarz Osrodek Badan Klinicznych - Bydgoszcz
    Bydgoszcz, 85-068, Poland
  • Szpital Uniwersytecki Number 2 im. dr. Jana Biziela w Bydgoszczy
    Bydgoszcz, 85-168, Poland
  • Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
    Elblag, 82-300, Poland
  • Indywidualna Specjalistyczna Praktyka Lekarska Lek. Med. Barbara Bazela
    Elblag, 82-300, Poland
  • Malopolskie Badania Kliniczne
    Krakow, 30-002, Poland
  • Grazyna Pulka Specjalistyczny Osrodek All-med
    Krak, 30-033, Poland
  • Pratia MCM Krakow
    Krak, 30-510, Poland
  • AMED Centrum Medyczne
    Lodz, 91-363, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej Lecznica Mak-Med Spolka Cywilna
    Nadarzyn, 05-830, Poland
  • Centrum Badan Klinicznych S.C.
    Poznan, 60-773, Poland
  • Ai Centrum Medyczne
    Poznan, 61-113, Poland
  • Nasz Lekarz Przychodnie Medyczne
    Torun, 87-100, Poland
  • Rheuma Medicus Zaklad Opieki Zdrowotnej
    Warszawa, 02-118, Poland
  • Ars Rheumatica - Reumatika Centrum Reumatologii
    Warszawa, 02-691, Poland
  • Centrum Medyczne AMED Warszawa Targowek
    Warszawa, 03-291, Poland
  • WroMedica
    Wroclaw, 51-685, Poland
  • Centrum Medyczne Oporow
    Wroclaw, 52-416, Poland
  • Chelyabinsk Regional Clinical Hospital
    Chelyabinsk, 454076, Russian Federation
  • Scientific Research Medical Complex
    Kazan, 420097, Russian Federation
  • Medical Center Revma-Med
    Kemerovo, 650070, Russian Federation
  • Clinic on Maroseyka
    Moscow, 101000, Russian Federation
  • Medical Center Health Family
    Novosibirsk, 630099, Russian Federation
  • State Healthcare Institution of the Republic of Karelia-Republican Hospital im.V.A.Baranova
    Petrozavodsk, 185019, Russian Federation
  • Polyclinic of Private Security Personnel
    Saint Petersburg, 192007, Russian Federation
  • Clinical Rheumatological Hospital Number 25
    Saint-Petersburg, 190068, Russian Federation
  • LLC Medical Consultation and Research Center-Practice
    Yarolavl, 150003, Russian Federation
  • Clinical Hospital named after NA Semashko
    Yaroslavl, 150023, Russian Federation
  • Hospital Universitario Reina Sofia
    Cordoba, 14004, Spain
  • Hospital Universitario de Fuenlabrada
    Fuenlabrada, 28942, Spain
  • Hospital Universitario Ramon Y Cajal
    Madrid, 28034, Spain
  • Corporacio Sanitaria Parc Tauli
    Sabadell, 08208, Spain
  • Hospital Nuestra Senora de la Esperanza
    Santiago de Compostela, 15705, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Bradford Teaching Hospitals NHS Foundation Trust
    Bradford, BD5 0NA, United Kingdom
  • The Princess Alexandra Hospital NHS Trust
    Harlow, CM20 1QX, United Kingdom
09

References and documents

Publications

  • Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, Kim J, Singhal S, Nowak M, Banerjee S. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022 Jun;81(6):815-822. doi: 10.1136/annrheumdis-2021-221664. Epub 2022 Mar 3. PubMed 35241426 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Apr 2020, 12 months.

Results were first posted in May 2021, 1 year after primary completion.

Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2019
First posted
Mar 19, 2019
StartActual
Apr 1, 2019
Primary completionActual
Apr 27, 2020
CompletionActual
Jan 27, 2021
Results first posted
May 17, 2021
Last update
Feb 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03881059
Responsible party
Sponsor
First posted
Mar 19, 2019
Start date
Apr 1, 2019
Primary completion
Apr 27, 2020
Completion
Jan 27, 2021
Results posted
May 17, 2021
Last update
Feb 15, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Deucravacitinib · Ustekinumab

Start the discussion